CLEC9A and ovarian carcinoma: Nevertheless, to the best of our knowledge, this is the first study to demonstrate the effectiveness of murine CD8α+ DCs in an ovarian cancer mouse model, suggesting that cDC1 vaccines represented by CD141+ Clec9a+ cells may be an effective immunotherapy in patients with ovarian cancer.